These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 16932528)

  • 1. Should neutralizing antibodies be monitored during interferon-beta treatment for multiple sclerosis?
    Oger J; Gibbs E
    Nat Clin Pract Neurol; 2006 Feb; 2(2):76-7. PubMed ID: 16932528
    [No Abstract]   [Full Text] [Related]  

  • 2. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
    Horowski R; Stürzebecher CS; Kapp JF
    Funct Neurol; 2001; 16(2):117-28. PubMed ID: 11495417
    [No Abstract]   [Full Text] [Related]  

  • 3. [Interferon beta-1a].
    Taéron C
    Rev Infirm; 2004 May; (101):39-40. PubMed ID: 15984751
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferon causes no myasthenia in a seropositive patient with multiple sclerosis.
    Shimizu H; Kataoka H; Kawahara M; Hirano M; Furiya Y; Ueno S
    Clin Neurol Neurosurg; 2007 Apr; 109(3):277-8. PubMed ID: 17118531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Will there soon be a sub-type specific treatment? New approaches to multiple sclerosis therapy].
    MMW Fortschr Med; 2008 Apr; 150(15):17. PubMed ID: 18510111
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.
    Farrell R; Bendtzen K; Bertolotto A; Clark B; Comabella M; Deisenhammer F; Fogdell-Hahn A; Giovannoni G; Hartung HP; Hemmer B; Hillert J; Kappos L; Killestein J; Lindberg R; Montalban X; Polman C; Sorensen PS;
    J Int Med Res; 2008; 36(1):204-8; author reply 208-10. PubMed ID: 18230281
    [No Abstract]   [Full Text] [Related]  

  • 7. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E; Vécsei L
    Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-beta1a treatment for multiple sclerosis.
    Sandberg-Wollheim M
    Expert Rev Neurother; 2005 Jan; 5(1):25-34. PubMed ID: 15853471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interferon beta-1b retinopathy during a treatment for multiple sclerosis].
    Sommer S; Sablon JC; Zaoui M; Rozot P; Hosni A
    J Fr Ophtalmol; 2001 May; 24(5):509-12. PubMed ID: 11397988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug therapy of multiple sclerosis].
    Kinnunen E
    Duodecim; 1999; 115(4):403-7. PubMed ID: 11830889
    [No Abstract]   [Full Text] [Related]  

  • 11. [Ensuring the long-term effectiveness of MS treatment].
    Krankenpfl J; 2005; 43(7-10):235. PubMed ID: 16515305
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon beta for treatment of multiple sclerosis.
    Wilson BA
    Medsurg Nurs; 1995 Apr; 4(2):151-3. PubMed ID: 7711824
    [No Abstract]   [Full Text] [Related]  

  • 13. Pearls and pitfalls of interferon beta treatment for multiple sclerosis.
    Corona T; León C; Ruiz JL
    Neurologia; 1999 Nov; 14(9):467-8. PubMed ID: 10613023
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon-beta treatment in patients with childhood-onset multiple sclerosis.
    Mikaeloff Y; Moreau T; Debouverie M; Pelletier J; Lebrun C; Gout O; Pedespan JM; Van Hulle C; Vermersch P; Ponsot G
    J Pediatr; 2001 Sep; 139(3):443-6. PubMed ID: 11562627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [High doses of interferon in the treatment of multiple sclerosis].
    Muñoz D
    Rev Neurol; 2001 May 1-15; 32(9):899. PubMed ID: 11424041
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of interferon beta at the time of initial diagnosis of multiple sclerosis.
    Pender MP
    J Clin Neurosci; 2001 Jul; 8(4):381-2. PubMed ID: 11437589
    [No Abstract]   [Full Text] [Related]  

  • 17. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
    Bartosik-Psujek H; Stelmasiak Z
    Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should all patients with an initial diagnosis of multiple sclerosis be treated with beta interferon?
    Hodgkinson SJ
    J Clin Neurosci; 2001 Jul; 8(4):378-9. PubMed ID: 11437587
    [No Abstract]   [Full Text] [Related]  

  • 19. The treatment of multiple sclerosis with beta-interferon.
    Poser CM
    Neuroepidemiology; 2008; 31(3):157-8. PubMed ID: 18716413
    [No Abstract]   [Full Text] [Related]  

  • 20. Should all patients with an initial diagnosis of multiple sclerosis be treated with beta interferon? The case against.
    Macdonell R
    J Clin Neurosci; 2001 Jul; 8(4):379-81. PubMed ID: 11437588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.